Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: Cost-effectiveness in the US

Current Medical Research and Opinion

Volumn 26, Issue 1, 2010, Pages 151-162

  Tunis, Sandra L ^a   Minshall, Michael E ^a  

^a IQVIA   (United States)

Author keywords

Complications; Cost effectiveness; Costs and cost analysis; Diabetes mellitus, type 2; Health care costs; Self monitoring of blood glucose

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; ORAL ANTIDIABETIC AGENT; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; COST EFFECTIVENESS ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; SELF MONITORING; UNITED STATES; AGED; BLOOD; COHORT ANALYSIS; COST BENEFIT ANALYSIS; LONGITUDINAL STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; QUALITY ADJUSTED LIFE YEAR;

ADMINISTRATION, ORAL; AGED; BLOOD GLUCOSE SELF-MONITORING; COHORT STUDIES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 77649197568     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903400071     Document Type: Article

References (61)

1. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care 2008;31:1-20
2. US Department of Health and Human Services, National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Atlanta, GA: Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/diabetes/pubs/factsheet07.htm [Last accessed 4 September 2009]
3. Davidson MB. Counter point: self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: a waste of money (Editorial). Diabetes Care 2005;28:1531-3 (Pubitemid 40756733)
4. Schnell O, Hummel M, Weber C. Economic and clinical aspects of diabetes regarding self-monitoring of blood glucose. Diabetes Technol Ther 2008; 10:S72-S81 (Pubitemid 351725053)
5. Owens DR. History and vision: what is important for patients with diabetes? Diabetes Technol Ther 2008;10:S5-S9 (Pubitemid 351725052)
6. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006;295: 1688-97
7. Welschen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 2005;28:1510-17 (Pubitemid 40756728)
8. Sarol Jr. J, Nicodemus Jr. N, Tan K, et al. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). Curr Med Res Opin 2005; 21:173-84
9. Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin 2006; 22:671-81
10. Towfigh A, Romanova M, Weinreb JE, et al. Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis. Am J Manag Care 2008;14:468-75 (Pubitemid 352031003)
11. McAndrew L, Schneider SH, Burns E, Leventhal H. Does patient blood glucose monitoring improve diabetes control?: a systematic review of the literature. Diabetes Edu 2007;33:991-1011
12. Guerci B, Drouin P, Grange V, et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab 2003; 29:587-94 (Pubitemid 38082160)
13. Murata GH, Shah JH, Hoffman RM, et al. Intensified blood glucose monitoring improves glycemic control in stable, insulin-treated veterans with type 2 diabetes: The Diabetes Outcomes in Veterans Study (DOVES). Diabetes Care 2003;26:1759-63 (Pubitemid 36929116)
14. Barnett AH, Krentz AJ, Strojek K, et al. The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab 2008;10:1239-47
15. Muchmore DB, Springer J, Miller M. Self-monitoring of blood glucose in overweight type 2 diabetic patients. Acta Diabetol 1994;31:215-19
16. Schwedes U, Siebolds M, Mertes G, Group SS. Meal-related structured self-monitoring of blood glucose: effect on diabetes control in noninsulin-treated type 2 diabetic patients. Diabetes Care 2002;25:1928-32 (Pubitemid 41071046)
17. Davis WA, Bruce DG, Davis TM. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Freemantle Diabetes Study. Diabetes Care 2006;29:1764-70 (Pubitemid 44156627)
18. Davis WA, Bruce DG, Davis TM. Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. Diabetologia 2007;50:510-55
19. Davidson MB, Castellanos M, Kain D, Duran P. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med 2005; 118:422-5 (Pubitemid 40461003)
20. Schutt M, Kern W, Krause U, et al. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24 500 patients from 191 centers in Germany and Austria. Exper Clin Endocrinol Diabetes 2006;114:384-8 (Pubitemid 44265571)
21. Farmer A, Wade A, Goyder E, et al. Impact of self-monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007;335:132-9
22. O'Kane MJ, Bunting B, Copeland M, Coates VE. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008;386:1174-7 (Pubitemid 351809278)
23. Scherbaum WA, Ohmann C, Abholz HH, et al. Effect of the frequency of self-monitoring of blood glucose in patients with type 2 diabetes treated with oral antidiabetic drugs -a multi-centre, randomized controlled trial. PLoS ONE 2008;3:1-5. Available at: www.plosone.org [Last accessed 15 December 2008]
24. Karter AJ, Ackerson LM, Darbinian JA, et al. Self-monitoring of blood glucose levels and glycemic control: The Northern California Kaiser Permanente Diabetes Registry. Am J Med 2001;111:1-9
25. Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29: 1757-63 (Pubitemid 44156626)
26. Simon J, Gray A, Clarke P, et al. Cost-effectiveness of self-monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM Trial. BMJ 2008;336:1177-80 (Pubitemid 351809279)
27. Klonoff DC. New evidence demonstrates that self-monitoring of blood glucose does not improve outcomes in type 2 diabetes -when the practice is not applied properly. J Diabetes Science Technol 2008;2:342-8
28. Palmer AJ, Dinneen S, Gavin III JR, et al. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin 2006;22:861-72 (Pubitemid 43875554)
29. Tunis SL, Minshall ME. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the United States. Am J Manag Care 2008;14:131-40 (Pubitemid 351367356)
30. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20:S5-S26 (Pubitemid 39349905)
31. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004; 20:S27-S40 (Pubitemid 39349906)
32. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27: 2262-5
33. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey (NHANES) 1999-2000 Dataset: Diabetes Survey. US Department of Health and Human Services, Hyattsville, MD, 2000. Available at: http://www.cdc.gov/nchs/data/ nhanes/spq-di.pdf [Last accessed 3 March 2008]
34. Miller CD, Phillips LS, Tate MK, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000;23:444-8 (Pubitemid 30185784)
35. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-8 (Pubitemid 30414188)
36. Klein R, Klein BEK. Vision disorders in diabetes. In: Harris MI, Cowie CC, Stern MP (eds). Diabetes in America, 2nd edn. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, 1995. Report number 95-1468. Available at: http://diabetes.niddk. nih.gov/dm/pubs/america/contents.htm (Last accessed 7 July 2007)
37. Braändle M, Zhou H, Smith BRK, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-4 (Pubitemid 36993316)
38. Massing MW, Foley KA, Sueta CA, et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes Care 2003;26:991-7 (Pubitemid 36929237)
39. McFarlane SI, Jacober SJ, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-23 (Pubitemid 41071193)
40. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25: 1017-38
41. DRG Desk Reference. The ultimate resource for improving DRG assignment practices. Salt Lake City, UT: Ingenix, 2006
42. Shearer A, Scuffham P, Gordois A, Oglesby A. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the US Diabetes Care 2003;26:2305-10 (Pubitemid 36993317)
43. Bullano MF, Al-Zakwani IS, Fisher MD, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005;21:291-8 (Pubitemid 40469905)
44. Drug Topics Redbook. Medical Economics Company (ed.) Montvale, NJ: Thomson PDR, 2006
45. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-7 (Pubitemid 29517951)
46. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001;27:347-51 (Pubitemid 32290859)
47. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index for Medical Care Services, 2006. Available at: http://www.bls.gov/cpi (Last accessed 1 September 2009)
48. ISPOR Global Health Care Systems Road Map. Reimbursement Processes Around the World. Available at: http://www.ispor.org/HTARoadMaps (Last accessed 8 June 2009)
49. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22:340-9 (Pubitemid 34791321)
50. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
51. Begg S, Vos T, Barker B, et al. The Burden of Disease and Injury in Australia 2003. Australian Institute of Health and Welfare, 2007. Available at: http://www.aihw.gov.au/publications/index.cfm/title/10317 (Last accessed 3 March 2008)
52. Carrington AL, Mawdsley SK, Morley M et al. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996; 32:19-25 (Pubitemid 26191382)
53. National Institute for Health and Clinical Excellence (NICE). Guidance on the use of long-acting insulin analogues for the treatment of diabetes-insulin glargine, Technology Appraisal Guidance Report No. 53, 2002. Available at: http://www.nice/org.uk/nicemedia/pdf/53 (Last accessed 20 April 2008)
54. Halpern EF, Weinstein MC, Hunink MGM, et al. Representing both first-and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000;20:314-22 (Pubitemid 30470727)
55. Briggs A, Wonderling D, Mooney C. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40 (Pubitemid 27384638)
56. Heinemann L, Koschinsky T. Clinical application and challenges of blood glucose measurement technology for self-monitoring. Diabetes Technol Ther 2008;10:S27-S34 (Pubitemid 351725045)
57. Bajkowska-Fiedziukiewicz A, Cypryk K, Kozdraj T, et al. Self-monitoring of blood glucose and treatment outcomes in type 2 diabetic patients. Pol Arch Med Wewn 2008;118:267-72 (Pubitemid 351839447)
58. Klonoff DC, Bergenstal RM, Blonde L, et al. Consensus report of the coalition for clinical research-self-monitoring of blood glucose. J Diabetes Science Technol 2008;2:1030-52
59. Fairman KA, Motheral BR. Do decision-analytic models identify cost-effective treatments?. A retrospective look at helicobacter pylori eradication. J Manag Care Pharm 2003;9:430-40
60. Skyler JS, Bergenstal RM, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. Diabetes Care 2009;32:187-92
61. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52 (Pubitemid 38660393)